Overview of Streptomycin sulfate

What Type of Medicine is Streptomycin Sulfate? (Definition and Classification)

Streptomycin sulfate is a potent, bactericidal Aminoglycoside antibiotic used to eliminate specific, susceptible microorganisms that cause serious systemic bacterial infections and is classified as an Antituberculosis agent. This substance belongs to a pharmacological class of antibiotics that act against certain severe pathogens. As an aminoglycoside, it works by inhibiting protein synthesis, which stops the growth of specific types of bacteria. Its characteristic as a first-in-class agent for tuberculosis is established for its role in treatment outcomes and its application in global public health.

What is the Composition and Origin of Streptomycin? (Form and Components)

The active ingredient in the medication is Streptomycin, which is prepared as the stable sulfate salt to ensure solubility and suitability for injection. Streptomycin is a naturally derived substance, originally isolated from the soil-dwelling bacterium Streptomyces griseus. The drug is supplied primarily as a sterile powder for reconstitution or a solution for injection, meaning it is prepared using an aqueous diluent for parenteral administration. This allows the active component to be delivered directly into the body's circulation to combat systemic infection, distinguishing it from oral antibiotics.

Why is Streptomycin Sulfate Considered an Essential Medicine? (General Therapeutic Value)

Streptomycin is utilized for its ability to act as a protein synthesis inhibitor, a mechanism that directly kills susceptible bacteria. Its general therapeutic purpose is the elimination of specific severe pathogens, positioning it as a primary treatment option. It is a single-active-ingredient product used for managing diseases such as Tuberculosis, Plague, and Tularemia, addressing the underlying pathological process by eliminating the responsible microorganisms. Its efficacy in treating these serious infections is established in clinical practice, and it remains included on the WHO Essential Medicines List.

Regulatory References

What side effects are possible with Streptomycin sulfate?

Possible Side Effects and Safety Information

The safety profile for Streptomycin sulfate, an Aminoglycoside antibiotic, is principally defined by its potential for neurotoxicity and ototoxicity, which are adverse effects involving the nervous system and inner ear. All safety information and classifications below reflect official government regulatory documents.

Spectrum of Officially Documented Adverse Reactions

The primary concern is ototoxicity, where vestibular dysfunction (including vertigo, nausea, and vomiting) is classified as common. Damage to the auditory system, which can result in deafness, is classified as less frequent. Other neurotoxic reactions, such as paresthesia of the face, are also common. Severe neurotoxic reactions, including encephalopathy and optic nerve dysfunction, are documented serious adverse reactions.

Systemic reactions include rash and fever, classified as common. Less frequent systemic and hematologic reactions include anaphylaxis and leucopenia. Disturbances in renal function, such as nephrotoxicity, are classified as rare, though azotemia is less frequent.

Safety Patterns and High-Risk Populations

The risk of severe neurotoxic reactions is sharply increased in patients with impaired renal function due to reduced clearance. Older adults are also noted to be more susceptible to serious side effects. The regulatory profile explicitly notes that vestibular dysfunction is cumulatively related to the total daily dose. Additionally, the drug can cause fetal harm when used during pregnancy due to the risk of fetal ototoxicity.

Safety limitations include the need to avoid concurrent or sequential use of other neurotoxic and/or nephrotoxic drugs due to the risk of additive toxicity. Furthermore, the label advises caution in patients with pre-existing VIII cranial nerve impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Streptomycin sulfate is formally characterized by exaggerated manifestations of known toxic effects on the neuromuscular, auditory, and renal systems. The most serious and life-threatening consequence documented in regulatory labeling is acute neuromuscular blockade, which can progress rapidly to severe respiratory depression or respiratory arrest.

Documented Manifestation	Life-Threatening Outcome
Profound muscular weakness	Acute respiratory arrest
Signs of ototoxicity (vertigo, hearing loss)	Severe nephrotoxicity

Immediate Actions and Management

Regulatory information strictly mandates that individuals seek immediate medical attention for any known or suspected overdose event. The drug must be discontinued promptly. As no specific antidote is known, management focuses on providing symptomatic and supportive treatment.

Specific official interventions include providing assisted ventilation for respiratory failure. The administration of calcium salts may be required as a measure to attempt to reverse the severe neuromuscular blockade. Hemodialysis is documented as a procedure that may be utilized to remove the drug, particularly in cases complicated by existing or acute renal impairment. Individuals with pre-existing kidney conditions are officially noted as being at an increased risk of severe toxicity.

Therapeutic Uses of Streptomycin sulfate

What Streptomycin Sulfate Treats: Main Uses and Benefits

This medication is primarily used to address conditions presenting with acute episodes and complex chronic diseases where supportive systemic antimicrobial management is appropriate. It is applied across domains where additional symptomatic support is needed.

The medication is commonly used across conditions presenting with acute episodes, including Plague, Tularemia, certain types of Infective Endocarditis, Brucellosis, and active forms of Tuberculosis. Its use is considered relevant in these complex contexts. It helps address symptom clusters related to systemic imbalance, such as high fever and profound physical deterioration, which often interfere with daily functioning.

Its role is relevant for managing specific forms of drug-resistant TB and challenging zoonotic infections. It contributes to easing the overall symptom load in situations where specific, susceptible bacteria are causing significant illness.

Quick Fact: Relief for Systemic Imbalance
This antibiotic is applied in conditions marked by increased physiological stress, where it helps address symptom clusters related to systemic imbalance, such as fever and involuntary body weight loss associated with chronic or acute systemic infection.

Regulatory References

FDA Drug Labeling for Streptomycin

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Streptomycin Sulfate

Official regulatory documentation defines eligibility for streptomycin sulfate based on absolute contraindications and strict conditional use requirements related to existing patient conditions, age, and reproductive status.

Eligibility Scope

Category	Regulatory Status	Description (Strictly Label-Based)
Populations for whom use is contraindicated	Absolute Prohibition	Patients with a known history of hypersensitivity to streptomycin or any other aminoglycoside antibiotic (due to cross-sensitivity).
Pregnancy and lactation eligibility status	Contraindicated/Conditional	Pregnancy is generally contraindicated due to the drug's confirmed ability to cross the placental barrier and cause fetal ototoxicity (congenital deafness). Use during lactation requires caution.
Condition-specific eligibility rules	Conditional/Restricted Use	Impaired renal function or pre-renal azotemia sharply increases the risk of severe neurotoxic reactions. Use is restricted and requires careful dose reduction and monitoring.
Age-related eligibility rules	Restriction/Caution	Older adult patients are considered more susceptible to neurotoxicity. Use in very young infants requires caution due to the risk of central nervous system depression from excessive dosing.

Resulting Eligibility Structure

Regulatory documents establish absolute non-eligibility for individuals with a prior aminoglycoside allergy and for pregnant patients. For all other populations, eligibility is defined by conditional use, where patients with impaired renal function, pre-existing hearing impairment, or advanced age are permitted to use the drug only under special regulatory conditions due to a heightened risk of irreversible damage.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents define the interaction profile of Streptomycin sulfate primarily through clinically significant pharmacodynamic effects, which generally involve either potentiating toxicity or reducing efficacy.

Documented Interacting Categories

Interacting Category	Practical Implication as Stated in Official Sources
Neurotoxic and/or Nephrotoxic Drugs	Concurrent or sequential use is avoided due to the increased risk of severe neurotoxicity and nephrotoxicity. This includes other aminoglycosides, certain cephalosporins (e.g., cephaloridine), platinum compounds (e.g., cisplatin), and amphotericin B.
Potent Ototoxic Agents (e.g., Loop Diuretics)	Co-administration of strong loop diuretics, such as ethacrynic acid and furosemide, potentiates the risk of ototoxicity (damage to the inner ear).
Neuromuscular Blocking Agents	Streptomycin increases the effects of muscle relaxants (e.g., succinylcholine, rocuronium) by pharmacodynamic synergism, elevating the risk of respiratory depression and paralysis. This risk is particularly noted after anesthesia.
Live Bacterial Vaccines	Streptomycin decreases the efficacy of certain live bacterial vaccines (e.g., BCG, typhoid) due to its antibacterial activity, leading to a regulatory restriction against concurrent use.

The drug's interaction constraints focus on avoiding combinations that significantly raise the likelihood of established toxicities or antagonize the therapeutic action of other products.

Mechanism of Action

How Streptomycin Sulfate Works

Streptomycin sulfate induces a bactericidal effect by selectively binding to the 30S subunit of the bacterial ribosome. This critical molecular action immediately disrupts the machinery responsible for protein synthesis.

This binding initiates a mechanistic cascade by causing the ribosome to severely misread the messenger RNA (mRNA) genetic code. This alters the signaling sequence, leading to the incorporation of incorrect amino acids and the rapid production of defective, truncated, or non-functional proteins. This process is known as mistranslation.

The accumulation of these faulty proteins is the key factor in the final physiological effect, as they are improperly incorporated into the bacterial cell membrane. This event compromises the cell's structural integrity and leads to the irreparable collapse of its barrier function, ultimately resulting in cell lysis and the loss of cell viability.

Dosage and Administration Information

How to Use Streptomycin Sulfate

Streptomycin sulfate is administered through the parenteral route—meaning via deep intramuscular (IM) injection or as a slow intravenous (IV) infusion—to ensure systemic delivery. The medication is supplied as a sterile powder that must be reconstituted with a suitable diluent, such as Water for Injection, immediately prior to its use. This preparation step must be completed under supervised conditions, as the drug should not be mixed with other agents in the same syringe or infusion solution.

Official Dosing and Frequency Patterns

The frequency and total dose are strictly established and vary according to the specific infection being treated. The drug is typically used as part of a multi-drug combination regimen.

Indication (General Regimen)	Adult Dosing Schedule	Frequency Pattern
Tuberculosis (Daily Phase)	15 mg/kg IM, generally capped at 1 gram per day	Once Daily
Tuberculosis (Intermittent Phase)	25 to 30 mg/kg IM	Two or Three Times Weekly
Severe Systemic Infections	1 to 2 grams daily, often divided	Once or Twice Daily

Administration Requirements and Adjustments

For Tuberculosis, the treatment course is often long-term, lasting a minimum of one year, with Streptomycin used during the initial phase. For infections like Plague or Tularemia, the treatment is typically a short course, lasting 7 to 14 days or until the patient has remained without fever for five to seven days.

Dosage adjustments are mandatory for specific patient populations. Clinical protocols specify a reduced dosage for older adults (over 60 years) and a frequency/dose reduction for patients with renal impairment, with the amount determined by the degree of kidney function. Administration should occur in a clinical setting with available patient monitoring.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Streptomycin sulfate, an aminoglycoside antibiotic, has a long history of use, but its role in current clinical practice is primarily reserved for specialized, combination regimens. It is rarely used as a first-line treatment due to the development of bacterial resistance and the availability of newer, less toxic alternatives.

Role in Multi-Drug Resistant Tuberculosis (MDR-TB)

Clinical evidence confirms that streptomycin retains a critical role as a second-line injectable agent in the treatment of multidrug-resistant tuberculosis (MDR-TB). Its inclusion is typically based on individualized treatment regimens, where resistance to other core antibiotics has been confirmed. However, studies show a significant and increasing rate of resistance to streptomycin itself, which impacts its overall utility and requires careful pre-treatment susceptibility testing.

Other Specialized Indications

Research and clinical guidelines continue to support the use of streptomycin in combination with other agents for specific, serious bacterial infections for which it remains effective. These include certain zoonotic diseases like tularemia (Francisella tularensis) and plague (Yersinia pestis). Additionally, it is sometimes used in synergistic regimens to treat certain types of bacterial endocarditis (infection of the heart lining), particularly when the causative organism shows resistance to gentamicin.

Drug Delivery and Risk Mitigation Research

Recent research has explored methods to potentially reduce the drug's known toxicities, which primarily involve ototoxicity (damage to hearing and balance) and nephrotoxicity (kidney damage). Early-stage studies have investigated novel delivery systems, such as streptomycin sulfate-loaded niosomes, to improve the drug's therapeutic window and potentially lower systemic exposure, though these technologies are not yet in clinical use. Monitoring of patients’ hearing and renal function remains a standard and essential component of treatment protocols.

Frequently Asked Questions (FAQ)

Common questions about Streptomycin sulfate (FAQ)

Q: What other types of bacterial infections, besides TB, is Streptomycin sulfate used for?

Official product information states that Streptomycin sulfate is indicated for specific, serious systemic infections. These include certain zoonotic diseases like plague and tularemia, as well as certain forms of bacterial endocarditis. Its inclusion in treatment is based on the specific susceptible microorganism identified.

Q: Is Streptomycin sulfate a common first-line antibiotic?

Official documents describe this medicine as being primarily reserved for serious systemic infections caused by susceptible organisms. In tuberculosis treatment, it is often utilized when resistance to first-line drugs is suspected or confirmed. Therefore, it is typically not classified as a common, initial antibiotic choice for most general bacterial infections.

Q: Where did the drug Streptomycin originally come from, historically?

Regulatory information acknowledges that Streptomycin is a naturally derived substance. It was originally isolated from a type of soil bacterium known as Streptomyces griseus. This fact establishes its historical significance as one of the first antibiotics effective against tuberculosis.

Q: Does Streptomycin sulfate treat infections caused by common bacteria like Staphylococcus or Pseudomonas?

Regulatory documents indicate that the drug is used against specific, susceptible organisms like those causing plague and tularemia. The official product information notes that it is considered less effective against many common bacteria, such as Pseudomonas aeruginosa. A healthcare professional determines if the drug is appropriate based on laboratory testing of the specific organism.

Q: Is it normal to feel pain or soreness at the site of the injection?

Soreness or discomfort at the injection site is recognized in the official safety profile as a reported adverse reaction. This potential effect is noted in the drug's regulatory documentation.

Q: Do patients need special monitoring, like blood tests or hearing checks, while receiving Streptomycin sulfate?

Official labeling strongly states that this medicine should only be used when adequate facilities are available for testing. This includes both laboratory testing to monitor kidney function and audiometric testing to monitor hearing. Monitoring of renal function and hearing is a required part of treatment protocols.

Q: What are the early signs of possible hearing damage from Streptomycin sulfate?

Regulatory information indicates that the first warnings of inner ear damage may include symptoms like headache, nausea, or vomiting. Additionally, patients may experience ringing in the ears (tinnitus), dizziness, or a sudden change in their sense of balance. If these occur, seeking medical guidance is noted as appropriate.

Q: What are the signs of potential kidney problems that patients should be aware of while taking Streptomycin sulfate?

While laboratory tests are necessary for accurate monitoring, official labeling notes that signs of potential kidney issues can include feeling an increase in thirst, noticing swelling of the feet or lower legs, or observing changes in the amount or frequency of urination. These potential changes are noted in the safety information as signals that should be discussed with a healthcare provider.

Q: Can Streptomycin sulfate affect a patient's vision or cause eye pain?

Official safety information documents that severe neurotoxic reactions are possible with this medicine. These rare reactions may involve optic nerve dysfunction, which can result in symptoms such as impaired vision or blurred vision that require medical evaluation.

Q: What are the signs of a severe allergic reaction to Streptomycin sulfate?

Regulatory documents list anaphylaxis as a potential serious reaction. Signs of a severe allergic response can include a widespread skin rash or hives, swelling of the face, lips, or tongue, and difficulty or shortness of breath. Such symptoms are described as severe and require prompt medical evaluation.

Q: Is diarrhea that happens months after stopping Streptomycin sulfate a known potential concern?

Official regulatory documents include a caution regarding an antibiotic-associated diarrhea. This specific and severe type of diarrhea can sometimes begin up to two months after the medicine has been discontinued. This potential effect is noted in the drug's safety information.

Q: Is there an age limit for who can receive Streptomycin sulfate injections?

The official documentation does not set an absolute age limit for treatment. However, it specifically requires a reduced dosage and frequent monitoring for patients over 60 years old. Additionally, caution is noted for use in very young infants. This caution is related to the potential risk of effects on the central nervous system in this population.

Q: What is the reason for the contraindication regarding other aminoglycosides?

Regulatory documents state that using Streptomycin sulfate concurrently or sequentially with other aminoglycoside antibiotics is avoided. This restriction is due to the potential for additive or potentiated toxicity, which specifically increases the risk of damage to the kidneys (nephrotoxicity) and the nerves/inner ear (neurotoxicity).

Q: How does Streptomycin sulfate interact with common over-the-counter vitamins or mineral supplements?

Regulatory guidance advises discussing the use of all supplements and vitamins with a healthcare team while using this medicine. Some medical literature suggests that the use of this drug may require the monitoring of certain vitamin levels, such as Vitamin B6 and B12.

Q: Does having certain pre-existing conditions increase the risk of drug interactions?

Yes, official documents establish that patients with certain pre-existing conditions are at a heightened risk. Specifically, individuals with impaired renal (kidney) function or pre-existing hearing/nerve problems are noted to have a greater likelihood of experiencing severe adverse effects, requiring careful dose adjustment and monitoring.

Q: Does having a history of hearing loss in my family affect the safety of using Streptomycin sulfate?

Regulatory information indicates that patients may be at a higher risk of developing hearing loss if their mother has a history of hearing loss when using Streptomycin or similar medicines. Due to this potential genetic susceptibility, informing a prescriber about family medical history is noted as important.

Q: Can children or infants be treated with Streptomycin sulfate, and are there special precautions?

The drug can be used in children, with dosage determined according to weight. Official documentation advises caution for use in very young infants. This caution is related to the increased risk of effects on the central nervous system in this population.

Q: Does having a condition like HIV or AIDS change the way Streptomycin sulfate is used?

Regulatory information notes that the treatment of tuberculosis has become more complex in patients with concomitant HIV infection. These patients may require a longer treatment period and a different management approach, as determined by their clinical team.

How should Streptomycin sulfate be stored and disposed of?

How to Store and Dispose of Streptomycin Sulfate

Official regulatory documents define specific requirements for the storage, protection, and disposal of Streptomycin sulfate (sterile powder for reconstitution).

Storage Requirements

Condition	Requirement
Temperature	Typically requires refrigeration (2–8, C) to maintain long-term chemical stability. Excess heat must be avoided.
Container Security	Containers must be kept tightly closed and stored in a dry place due to the product's hygroscopic nature.
Access	The medicine must be secured according to the regulatory instruction: “Store locked up” and “Keep out of reach of children.”

Disposal Mandates

Disposal must follow official environmental safety rules because the product should not be released into the environment or down the drain, due to its toxicity to aquatic life. Contents and containers must be discarded through an approved waste disposal plant or an authorised special waste collection point.

Streptomycin sulfate